Rosuvastatin
Crestor · Ezallor · ZD4522 · rosuvastatin calcium
Last updated
At a glance
Overview
Rosuvastatin has quietly become the default lipid tool for anyone running gear seriously. It's the most potent statin per milligram on the market, it's hydrophilic (so it doesn't flood muscle tissue the way simvastatin or atorvastatin do), and it bypasses CYP3A4 almost entirely — meaning you can stack it with anastrozole, tadalafil, azoles, and the usual cycle support without meaningful PK interactions. For physique-focused users watching LDL and ApoB climb during an oral blast, that combination is hard to beat.
The use case is straightforward: oral AAS crush HDL and spike LDL, injectables do it more slowly, and waiting for lipids to "bounce back" post-cycle is how people end up with plaque they didn't plan on. Rosuvastatin at 5–10 mg/day holds LDL in range through a cycle, pairs cleanly with fish oil and citrus bergamot, and runs straight through PCT without interfering with clomid, tamoxifen, or enclomiphene. The longevity-minded crowd chasing an ApoB <60 target uses it the same way — JUPITER validated that exact protocol.
"The rates of major cardiovascular events were reduced by 44% with rosuvastatin as compared with placebo among apparently healthy persons with elevated levels of high-sensitivity C-reactive protein." — Ridker et al., NEJM (2008)
Below we'll break down rosuvastatin dosage across cycle intensities, the on-cycle lipid protocol (when to start, when to stop, what to stack), side effects and how to distinguish statin myalgia from training soreness, and how rosuvastatin compares to pitavastatin, atorvastatin, and ezetimibe for PED users.
How Rosuvastatin works
HMG-CoA Reductase Inhibition — The Core Mechanism#
Rosuvastatin competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in the hepatic mevalonate pathway that converts HMG-CoA into mevalonate — the committed step toward cholesterol synthesis. When hepatocytes can't synthesize cholesterol internally, they compensate by upregulating surface LDL receptors (LDLR), which then pull circulating LDL, VLDL remnants, and other apoB-containing particles out of plasma for clearance.
Translation for the on-cycle user: the liver, which is getting hammered by oral AAS suppression of HDL and upregulation of hepatic lipase, gets forced back into LDL-clearance mode. This is the single biggest lever you have against AAS-driven dyslipidemia, and rosuvastatin is the most potent molecule in the class per milligram.
"The greatest reductions in LDL cholesterol were achieved with rosuvastatin, which at 10 mg reduced LDL cholesterol by 46%, at 20 mg by 52%, and at 40 mg by 55%." — Jones PH, Davidson MH, Stein EA, et al. American Journal of Cardiology, 2003
Notice the logarithmic curve — doubling from 10 to 20 mg buys you 6 percentage points, doubling again to 40 mg buys 3 more. This is why community dosing plateaus at 10 mg for most users and 20 mg for harsher orals.
Hydrophilicity and Hepatoselective Uptake#
Unlike simvastatin and atorvastatin (lipophilic, freely diffuse across membranes), rosuvastatin is hydrophilic and cannot simply drift into myocytes. It relies on the OATP1B1 transporter (SLCO1B1) — concentrated in hepatocytes — for active uptake into the liver. Muscle tissue lacks this transporter at meaningful density, so rosuvastatin stays where you want it (liver) and largely avoids where you don't (skeletal muscle).
This is the mechanistic basis for why rosuvastatin and pitavastatin became the PED community's preferred statins: lifters already run elevated baseline CK and don't need a lipophilic statin seeping into hard-trained muscle on top of that.
"Rosuvastatin appears to present lower risk for muscle side effects compared with lipophilic statins due to its limited capacity to enter extrahepatic tissues by passive diffusion." — Kostapanos MS, Milionis HJ, Elisaf MS. American Journal of Cardiovascular Drugs, 2010
The practical payoff: fewer dose reductions for myalgia, less interference with heavy training, and a cleaner separation between actual statin-induced muscle symptoms and ordinary DOMS.
Pleiotropic Effects — ApoB, Inflammation, Endothelium#
LDL-C is the lab number everyone tracks, but the particle count doing the damage is apoB. Rosuvastatin drops apoB roughly in parallel with LDL-C — often more so in AAS users, whose LDL-C can underestimate particle burden. For anyone targeting an Attia-style apoB <60 mg/dL, 5–10 mg rosuvastatin gets most people there without further escalation.
Beyond lipid lowering, rosuvastatin exerts effects independent of LDL reduction:
- hs-CRP reduction (~37%): damps systemic vascular inflammation
- Endothelial function: improves NO bioavailability and flow-mediated dilation
- Plaque stabilization: shifts plaques toward fibrous, less rupture-prone morphology
The JUPITER trial isolated these pleiotropic effects by enrolling subjects with normal LDL but elevated hs-CRP — exactly the profile of a healthy lifter whose bloodwork looks fine on paper but whose inflammatory signalling is elevated from training volume, body composition, or subclinical issues.
"The rates of major cardiovascular events were reduced by 44% with rosuvastatin as compared with placebo among apparently healthy persons with elevated levels of high-sensitivity C-reactive protein." — Ridker PM, Danielson E, Fonseca FAH, et al. New England Journal of Medicine, 2008
This is why rosuvastatin earns a longevity-framed use case independent of AAS lipid rescue — it has primary-prevention outcome data in people who don't look like statin candidates on LDL alone.
Pharmacokinetic Profile That Plays Nicely With Other Compounds#
Rosuvastatin's absorption is modest — ~20% oral bioavailability — driven by incomplete absorption and high first-pass hepatic extraction, exactly the kind of first-pass that keeps the drug in the liver rather than leaking to muscle.
"The absolute oral bioavailability of rosuvastatin was approximately 20%, with a mean time to peak plasma concentration (Tmax) of about 3 to 5 hours." — Martin PD, Warwick MJ, Dane AL, et al. Clinical Therapeutics, 2003
The critical advantage for anyone running a complex stack: rosuvastatin is not a CYP3A4 substrate. Only ~10% is metabolized, mostly by CYP2C9, and the rest is excreted unchanged in bile. That means:
- No meaningful interaction with anastrozole, exemestane, or tadalafil
- No grapefruit-juice problem
- No stacking conflict with most AAS metabolism pathways
- Compatible with azole antifungals, most antibiotics, and ketoconazole — which would destroy simvastatin
The real PK watch-outs are OATP1B1 inhibitors: cyclosporine (AUC up ~7×), gemfibrozil, and certain HIV protease inhibitors. These are the hard interaction rules; outside that list, rosuvastatin fits cleanly into almost any cycle support stack.
Long terminal half-life (~19 h) means timing is flexible — morning, evening, with or without food. Steady-state levels after 4–5 days mean lipid panels pulled less than a week after starting won't yet reflect full effect; wait 4 weeks for an accurate read.
Population PK Caveat — East Asian Exposure#
One mechanism-adjacent point that gets missed: East Asians show ~2× plasma exposure at the same dose compared with Caucasians, driven by OATP1B1 and BCRP polymorphisms that reduce hepatic uptake clearance.
"AUC and Cmax values were approximately 2-fold higher in Asian subjects compared with white subjects after administration of the same rosuvastatin dose." — Lee E, Ryan S, Birmingham B, et al. Clinical Pharmacology & Therapeutics, 2005
Practical rule: East Asian users start at 5 mg and cap at 20 mg, not 40 mg. Ignoring this roughly doubles the effective dose and drives up myopathy risk without adding meaningful LDL reduction — the dose-response curve is already flat at the top.
Protocol
| Level | Dose | Frequency | Notes |
|---|---|---|---|
| Low | 5–10 mg | Once daily | Documented entry-level range |
| Mid | 10–20 mg | Once daily | Most commonly studied range |
| High | 20–40 mg | Once daily | Any time of day — long half-life means timing is flexible. Food reduces AUC ~20% but doesn't meaningfully affect LDL lowering. East Asian users should halve starting and max doses due to ~2× exposure. |
Cycle length & outcomes
Documented cycle
4–52 weeks
Plateau after
52 wks
Cycle Length & Timing#
Rosuvastatin isn't a "cycle" in the AAS sense — it's a lipid tool you run alongside the cycle. No loading phase, no taper, no HPTA suppression to worry about. The only real question is when to start and when to stop, and the answer is: earlier than most people think on both ends.
Lipid damage from oral AAS shows up fast — harsh orals like superdrol or halotestin can crater HDL and spike LDL within 2 weeks. Waiting for mid-cycle bloodwork to show LDL at 200 before starting means you've already spent weeks with your lipids in the ditch. The smarter play is prophylactic: start rosuvastatin 1 week before orals hit, or at the first bloodwork showing LDL drifting above 130 or HDL below 30.
On the back end, lipids lag weeks behind AAS clearance. Running the statin through the first 4–6 weeks post-cycle catches the transitional phase where HDL is still suppressed and LDL is still elevated.
Dose by Goal#
| Goal | Cycle Length | Daily Dose |
|---|---|---|
| TRT-dose injectable maintenance | Continuous / 8–12 wk review | 5 mg |
| Moderate oral cycle (anavar, tbol) | Oral duration + 4 wk post | 5–10 mg |
| Harsh oral cycle (superdrol, winstrol, halo) | Oral duration + 4–6 wk post | 10 mg |
| Pre-blast lipid conditioning | Start 4 wk pre-cycle, run through | 10 mg |
| Long-term blast-and-cruise | Continuous | 5–10 mg |
| Post-cycle lipid recovery | 6–12 wk after last AAS | 5–10 mg |
| ApoB / hs-CRP optimization (off cycle) | Continuous | 5–10 mg |
Dose-response plateaus hard above 20 mg — going from 20 to 40 mg buys you ~3% more LDL reduction at meaningfully higher myopathy risk. Most physique-focused users never need to go above 10 mg.
"The greatest reductions in LDL cholesterol were achieved with rosuvastatin, which at 10 mg reduced LDL cholesterol by 46%, at 20 mg by 52%, and at 40 mg by 55%." — Jones PH et al., Am J Cardiol (2003)
East Asian users: halve everything. Starting dose 2.5–5 mg, cap at 20 mg. Plasma exposure runs roughly 2× higher at the same dose.
"AUC and Cmax values were approximately 2-fold higher in Asian subjects compared with white subjects after administration of the same rosuvastatin dose." — Lee E et al., Clin Pharmacol Ther (2005)
Onset & Timing Within the Day#
Meaningful LDL lowering appears within 7–14 days, with near-maximal effect by 4 weeks. Any mid-cycle bloodwork at week 4–6 will accurately reflect the protocol.
With a ~19-hour half-life, timing of dose is flexible — morning, evening, with or without food. Food reduces AUC by ~20% but doesn't change clinically meaningful LDL lowering. Pick whatever time you'll actually remember.
Bloodwork Cadence#
This is the ancillary that lives or dies by actual data. Dosing without bloodwork is guessing.
| Timepoint | What to Pull |
|---|---|
| Pre-cycle baseline | Full lipid panel, ApoB, hs-CRP, ALT/AST, CK, fasting glucose. Lp(a) once (lifetime). |
| Week 4–6 mid-cycle | Lipid panel + ApoB. Decide whether to start or uptitrate. |
| 4–6 wk post-cycle | Lipid panel + ApoB, ALT/AST |
| Cruise / chronic | Quarterly lipids + ApoB; annual CK and fasting glucose |
Track ApoB as the primary target, not LDL-C alone. AAS can distort the LDL-C / ApoB relationship, and ApoB is what actually drives atherogenesis. A reasonable on-cycle ceiling is ApoB <80 mg/dL; longevity-focused users push for <60.
CK interpretation needs context — heavy lifters run elevated CK at baseline. Track trends and correlate with actual symptoms (bilateral proximal muscle pain, weakness), not isolated numbers. A CK of 400 in a lifter who feels fine is not the same as a CK of 400 in a sedentary patient.
Tapering & Discontinuation#
No taper required. Rosuvastatin doesn't suppress endogenous cholesterol synthesis in a way that rebounds dangerously — when you stop, LDL returns toward your untreated baseline over 2–4 weeks. You can start and stop as needed without washout concerns.
The one exception: if you've been running it long-term and your lifestyle / diet hasn't changed, stopping will return LDL to pre-treatment levels. That's not a rebound — that's just biology. Don't confuse the two.
Stacking Within the Protocol#
The standard on-cycle lipid stack is additive and well-tolerated:
- Rosuvastatin 5–10 mg/day
- EPA+DHA 2–4 g/day (prescription-grade or high-purity OTC)
- Citrus bergamot 500–1000 mg/day
- Ezetimibe 10 mg/day when rosuvastatin alone at 10 mg isn't holding ApoB in range
- Daily Zone 2 cardio (30–45 min, 3–5×/wk)
"Rosuvastatin appears to present lower risk for muscle side effects compared with lipophilic statins due to its limited capacity to enter extrahepatic tissues by passive diffusion." — Kostapanos MS et al., Am J Cardiovasc Drugs (2010)
That hydrophilicity is why rosuvastatin became the community default over simvastatin or atorvastatin — muscle tissue doesn't concentrate it, and training-related soreness isn't compounded the way it is on lipophilic statins.
Rosuvastatin has no meaningful interaction with SERMs (tamoxifen, enclomiphene, clomid), AIs (anastrozole, exemestane), hCG, tadalafil, or any standard PCT drug. Run it straight through PCT — lipids are often at their worst during the transition, so this is exactly when you want coverage.
Hard interaction stops: concurrent cyclosporine (AUC ~7× higher), full-dose gemfibrozil, and certain HIV protease inhibitors. Fibrates in general increase myopathy risk — if you need both a statin and a fibrate for mixed dyslipidemia, fenofibrate is the safer pairing.
Risks & mistakes
Common (most users)#
-
Muscle aches / myalgia — the headline complaint, reported in ~5–10% of users. Lifters will feel it as diffuse, bilateral soreness that doesn't track with training volume (distinct from DOMS). Rosuvastatin is hydrophilic and penetrates muscle less than lipophilic statins, so incidence is lower than with simvastatin or atorvastatin.
"Rosuvastatin appears to present lower risk for muscle side effects compared with lipophilic statins due to its limited capacity to enter extrahepatic tissues by passive diffusion." — Kostapanos et al. 2010, Am J Cardiovasc Drugs
Mitigation: drop from 10 mg to 5 mg, or 5 mg every other day. CoQ10 100–200 mg/day is cheap insurance and anecdotally helps. If symptoms persist, switch to pitavastatin.
-
Mild transaminase bump (ALT/AST) — usually asymptomatic and within 1.5× ULN. Complicated by the fact that AAS (especially 17α-alkylated orals) already elevate these enzymes, so interpret the delta, not the absolute number. Mitigation: baseline bloodwork before starting the statin so you can separate statin effect from oral-AAS effect.
-
GI upset, headache, occasional insomnia — usually resolve within 1–2 weeks. Mitigation: take with the evening meal if it bothers your stomach; shift to morning dosing if sleep is affected. Timing is flexible with a 19-hour half-life.
-
Feeling "flat" on heavy training days — occasional community report, likely related to mild CoQ10 depletion and possibly modest reductions in intramuscular cholesterol (a testosterone precursor). Mitigation: CoQ10 200 mg/day; if it persists, drop to 5 mg.
Uncommon (dose-dependent or individual)#
-
CK elevation without symptoms — common incidental finding in lifters because training already drives CK up. A CK 2–3× ULN in an asymptomatic lifter is generally not a statin problem. Action: recheck CK 48–72 hours after a rest day. If it's still trending >5× ULN without explanation, drop the dose.
-
New-onset glucose dysregulation — small but real signal at 20 mg doses (JUPITER cohort), mechanism involves mild insulin resistance. Relevant if you're running GH, slin, or a heavy bulk. Bloodwork: fasting glucose and HbA1c at baseline and every 3–6 months on chronic use.
-
Proteinuria / hematuria — typically at 40 mg, usually transient and clinically silent. Bloodwork: urine dipstick and creatinine / eGFR on any panel, especially if you're also on AAS doses that already stress the kidneys.
-
Elevated exposure in East Asian users — not a side effect per se, but a PK reality: Asian users see roughly double the plasma exposure at the same dose.
"AUC and Cmax values were approximately 2-fold higher in Asian subjects compared with white subjects after administration of the same rosuvastatin dose." — Lee et al. 2005, Clin Pharmacol Ther
Mitigation: halve the starting dose (5 mg) and cap at 20 mg.
Rare but serious#
-
Rhabdomyolysis — the one that matters. Warning signs: severe, disabling muscle pain, muscle weakness, and dark cola-colored urine. Stop immediately and get labs (CK, creatinine, urinalysis). Risk factors: 40 mg dosing, OATP1B1 polymorphisms, concurrent OATP inhibitors (cyclosporine, gemfibrozil), severe dehydration, extreme training volume.
-
Clinically significant hepatotoxicity — rare. Persistent ALT/AST >3× ULN, especially with jaundice, RUQ pain, or dark urine, warrants stopping. Distinguish from the much more common oral-AAS-driven hepatotoxicity.
-
Immune-mediated necrotizing myopathy — very rare autoimmune syndrome that persists after stopping the statin. Presents as proximal weakness with very high CK that doesn't resolve on discontinuation. Requires rheumatology workup.
Hard contraindications#
- Pregnancy and breastfeeding — category X. Statins impair fetal cholesterol synthesis and development. Do not run rosuvastatin if you are pregnant, trying to become pregnant, or nursing.
- Active liver disease or unexplained persistent transaminase elevation >3× ULN.
- Concurrent cyclosporine — AUC increases ~7×, unacceptable myopathy risk.
- Concurrent gemfibrozil (full dose) — drives rosuvastatin exposure and rhabdomyolysis risk. Fenofibrate is the preferred fibrate if combination therapy is needed.
- History of rhabdomyolysis on any statin.
- Severe renal impairment (CrCl <30 mL/min) at doses above 10 mg.
Gender and PCT considerations#
No unique female considerations outside the pregnancy contraindication — dosing is identical to men. For women on AAS managing lipid damage from oxandrolone or primobolan, rosuvastatin is the same 5–10 mg/day tool.
Rosuvastatin is not hormonal, does not suppress the HPTA, and does not interact with SERMs or AIs (tamoxifen, clomid, enclomiphene, anastrozole, exemestane). You can — and generally should — run it straight through PCT, since the post-cycle transition is when HDL is at its lowest and LDL is still rebounding. Pulling the statin the moment you stop the cycle means you're unprotected through the worst of the lipid damage. Carry it 4–6 weeks into PCT, recheck lipids, and then decide whether to taper off or stay on at 5 mg as a chronic cruise-phase ancillary.
Stack & combine
Multipliers applied when these compounds run together. Values > 1 indicate a bonus on that axis. Tap a partner to expand the mechanism.
| Partner | Type | Lean | Fat loss | Recovery |
|---|---|---|---|---|
| synergistic | ×1.05 | ×1.00 | ×1.18 | |
| synergistic | ×1.00 | ×1.00 | ×1.00 | |
| additive | ×1.00 | ×1.03 | ×1.00 |
Featured in stacks1 curated protocol include Rosuvastatin
FAQ — Rosuvastatin
Where to buy
NextChems
Affiliate link — we may earn a commission at no cost to you.
- Rosuvastatin, 5mg - 60 capsules - Next ChemsBuy Rosuvastatin
Research & citations
5 studies cited on this page.
Conclusion
Rosuvastatin is the gold-standard statin for anyone running PEDs, oral AAS, or high-dose TRT and dealing with wrecked lipids. It packs strong LDL-lowering and proven cardiovascular risk reduction with a muscle side effect profile that beats older lipophilic statins.
Key takeaways:
- Standard dose: 5–10 mg once daily (as low as 2.5–5 mg for East Asian users)
- Start 1 week before orals or at the first sign of LDL >130; run at least 4–6 weeks post-cycle
- Pair with 2–4 g/day EPA+DHA and 500–1000 mg citrus bergamot for a complete lipid stack
- Once-daily dosing — food timing does not matter
- No meaningful adverse interaction with most AAS, AI, or peptide regimens
- Myalgia risk is lower than simvastatin/atorvastatin, but monitor for muscle symptoms if training hard
If you care about keeping ApoB and LDL in check while optimizing aesthetics or performance, rosuvastatin is straightforward to implement and far better tolerated than the scaremongers claim.
"The greatest reductions in LDL cholesterol were achieved with rosuvastatin...at 10 mg reduced LDL cholesterol by 46%..." — Jones PH, et al., Am J Cardiol (2003)
"Rosuvastatin appears to present lower risk for muscle side effects compared with lipophilic statins..." — Kostapanos MS, et al., Am J Cardiovasc Drugs (2010)